The company's primary activities involve entering into marketing and licensing agreements related to pharmaceutical products, with key products including Vicineum (a drug formerly developed by Sesen) for which Enzon may receive milestone and royalty payments. As of October 2026, Enzon and Viskase amended their merger agreement with Viskase stockholders set to own 55% and Enzon stockholders 45% of the combined company.
Cyborg Score Rationale
The company has a market capitalization of $3.9 million with minimal revenue and negative cash flow. The entity is essentially a shell company pursuing a merger with Viskase, operating with severely constrained resources and facing execution risk on its strategic transformation.
Top Insights
A 1-for-100 reverse stock split became effective March 24, 2026, reflecting aggressive capital restructuring
The company leverages net operating loss carryforwards as a strategic asset for acquisition platform value creation
Enzon trades on OTC markets and explicitly positions itself as an acquisition vehicle focused on using its public company status for transactions rather than operating as a traditional pharmaceutical manufacturer
Key merger terms include a reduction in Enzon's required closing cash and extension of the termination deadline to March 31, 2026
Named Competitors
SciClone Pharmaceuticals — Specialty pharmaceutical company
Arecor Therapeutics — Formulation technology and specialty pharma
VBI Vaccines — Immunology and vaccine developer
Recent Developments
(March 2026) Completed 1-for-100 reverse stock split and finalized Series C preferred stock exchange offer